Roivant Drug Shows 56% Success Against Lung Disease

A new experimental drug from biotech company Roivant just achieved remarkable results in treating a serious form of pulmonary hypertension, opening doors to better treatments for patients struggling with this dangerous lung condition.

The Phase 2 study showed the drug significantly improved blood flow, breathing ability, and heart health markers.